Pay in 4 interest-free payments of $5.67 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Search All MIN Lorem Company A LOC: Sector A Search All MIN Search by Name Search by Ticker ASX:RMD Healthcare Equipment and Supplies ResMed turns GLP-1 weight loss drugs from threat into market expansion story Fears that GLP-1 obesity drugs would shrink the pool of sleep apnoea patients needing CPAP therapy have given way to a fund manager consensus that the drugs are instead growing ResMed's addressable market by driving more people into the sleep channel
S3, Table S5), with the majority of studies focusing on a specific GLP-1RA drug, including 12 on exenatide, 2 on lixisenatide, 3 on dulaglutide, 1 on albiglutide, and 1 on semaglutide
Q.et al (2023b)
** kein Nhrstoffbezugswert vorliegend
121 Overall, these data accumulate to show that GLP-1 RAs provide not only metabolic and mitochondrial effects but also meaningful clinical impact for vascular and neuroendocrine protection that may ultimately decrease age-related decline in cardiovascular health, musculoskeletal health, and cognitive health
US$ 23.30
US$ 26.68
US$ 29.58
US$ 29.52
US$ 26.44
US$ 28.06
US$ 21.66
US$ 24.22
US$ 23.76
US$ 21.10
